Dallas, TX: ReportsandReports announce Merck & Co. Inc: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/8184-merck-co-inc-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Merck & Co.’s performance against key rivals in the prescription pharmaceutical sector
• Assess the strategic implications of Merck & Co.’s recent merger with Schering-Plough
• Analyze the impact of generic erosion across key Merck & Co. brands over 09-15 and how this threat will mitigate sales growth from new launches
• ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
• Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003-15 6
Financial performance, 2003-15 7
Merck & Co.: PharmaVitae forecasts at a glance 8
Strategic insight 9
Merck rises back up the ranks of Big Pharma following integration of Schering-Plough 9
Megamerger with Schering-Plough helps to shape Merck’s future 10
Schering-Plough merger engineered to boost pipeline and reduce generic drug exposure 11
Diversification will help Merck deflect rising competitiveness in the prescription pharmaceutical segment 14
SWOT analysis 16
Table of Contents 17
Table of figures 19
• Chapter 3 Quarterly news update 20
Latest quarterly sales 20
Latest comment 21
Q1 2010 21
Merck & Co: potential remains for HIV drug despite trial disappointment 21
Q3 2009 22
Merck & Co: dosing regime may hinder Isentress uptake 22
Q2 2009 23
Merck and AstraZeneca: rivals join forces in oncology 23
Latest prescription pharma product news 24
Q2 2010 24
Q1 2010 24
Latest corporate news 25
Q1 2010 25
Future product milestones 27
• Chapter 4 Company introduction 28
Key findings 28
Background 29
Key corporate developments 29
Highlights of Merck & Co.’s global restructuring plan 30
December 2006 update 31
Further restructuring announced in Q3 2008 31
Schering-Plough merger 31
M&A history 32
Divestments 32
Acquisitions 33
GlycoFi 33
Abmaxis 33
Sirna Therapeutics 34
NovaCardia 34
Schering-Plough 34
• Chapter 5 Company sales 35
Key findings 35
Prescription pharmaceutical sales and growth rate analysis, 2003-15 36
Historical analysis 37
Forecast analysis 37
Product analysis 38
Product analysis, 2003-09 39
Growth drivers 41
Growth resistors 41
Product analysis, 2009-15 42
Growth drivers 44
Growth resistors 45
Therapy area analysis 46
Geographic analysis 48
Launch/core/expiry analysis 50
Explanation of launch/core/expiry analysis 50
Launch analysis, 2009-15 51
Core analysis, 2009-15 53
Expiry analysis, 2009-15 54
Launch/core/expiry configuration, 2009-15 56
Molecule type analysis 57
Externalization analysis 59
• Chapter 6 Company financials 61
Key findings 61
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 62
Operating costs and profit analysis 63
Operating costs and profit analysis, 2003-09 64
Operating cost ratio and profit margin analysis, 2003-09 65
Operating cost ratio and profit margin analysis, 2009-15 66
Operating costs and profit analysis, 2009-15 67
• Chapter 7 Key products 68
Overview 68
Sitagliptin franchise 69
Summary 70
Sales forecast 73
Remicade/Simponi 75
Summary 76
Sales forecast 78
sentress 79
Summary 80
Sales forecast 81
ProQuad/MMRII/Varivax 82
Summary 83
Sales forecast 84
Singulair 85
Summary 86
Sales forecast 87
Zetia/Vytorin 88
Summary 89
Sales forecast 91
Saphris 92
Summary 93
Sales forecast 94
Cozaar/Hyzaar 95
Summary 96
Sales forecast 97
SCH 530348 99
Summary 100
Sales forecast 101
• Chapter 8 Appendix 102
References 102
Abbreviations 102
Exchange rates 104
About Datamonitor 105
About Datamonitor Healthcare 105
Datamonitor consulting 105
Disclaimer 107
ABBREVIATIONS
Browse all Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Publisher:- Datamonitor Market Research Reports
Browse all : http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Latest Report :-
Browse all Newly Published Market Research Reports
Related Reports:
Merck KGaA: PharmaVitae Profile
http://www.reportsandreports.com/reports/8512-merck-kgaa-pharmavitae-profile.html
Merck & Co. Inc.-Deals & Alliances Report
http://www.reportsandreports.com/reports/4371-merck-co-inc-deals-alliances-report.html
Merck & Co., Inc. – SWOT Analysis
http://www.reportsandreports.com/reports/2505-merck-co-inc-swot-analysis.html
Eli Lilly & Co.: PharmaVitae Profile
http://www.reportsandreports.com/reports/8202-eli-lilly-co-pharmavitae-profile.html
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
http://www.reportsandreports.com/reports/9080-takeda-pharmaceutical-co-ltd-pharmavitae-profile.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
